Amicus Therapeutics Inc FOLD:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
Last | 9:37 AM EST
12.04quote price arrow up+0.15 (+1.26%)
Volume
79,555
52 week range
6.25 - 25.39

...

Loading . . .

KEY STATS

  • Open11.94
  • Day High12.08
  • Day Low11.94
  • Prev Close11.89
  • 52 Week High25.39
  • 52 Week High Date12/22/20
  • 52 Week Low6.25
  • 52 Week Low Date03/16/20
  • Market Cap3.138B
  • Shares Out260.59M
  • 10 Day Average Volume8.87M
  • Dividend-
  • Dividend Yield-
  • Beta1.25
  • 1 Year % Change21.2

RATIOS/PROFITABILITY

  • EPS (TTM)-1.15
  • P/E (TTM)-10.48
  • Fwd P/E (NTM)-13.79
  • EBITDA (MRQ)-263.373M
  • ROE (MRQ)-67.97%
  • Revenue (MRQ)245.61M
  • Gross Margin (MRQ)88.37%
  • Net Margin (MRQ)-120.18%
  • Debt To Equity (MRQ)121.33%

EVENTS

  • Earnings Date03/01/2021
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest Amicus Therapeutics Inc News

QUOTE FINDER

Related Video

VIDEO1:0601:06
Amicus releases phase 3 results in Pompe disease trial

Profile

MORE
Amicus Therapeutics, Inc. is a biotechnology company focused on discovering, developing and delivering medicines for people living with rare metabolic diseases. The Company is engaged in developing a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; clinical-stage, treatment...
John Crowley J.D.
Chairman
Bradley Campbell
President
Daphne Quimi CPA
Chief Financial Officer
Samantha Prout CPA
Chief Accounting Officer
Ellen Rosenberg J.D.
General Counsel
Address
3675 MARKET STREET
Philadelphia, PA
19104
United States